WORLD JOURNAL OF PHARMACEUTICAL RESEARCH
Coden USA: WJPRAP Impact Factor 8.63
Volume 15, Issue 22, 1052-1080. Review Article ISSN 2277–7105

NEXT-GENERATION PHARMACEUTICAL INNOVATIONS IN MENINGOCOCCAL DISEASE: PRECISION VACCINE DELIVERY, NANOTECHNOLOGY-ENABLED THERAPEUTICS, AND ADVANCED FORMULATION ENGINEERING

D. Steven Paul[1], V. Sudheer[1], B. Mastan[1], Prasanna Kumar Desu[1], Anusha Raouri[2], Kasietti Ashok Babu[3], Yaparthi Suneetha[3], David Raju Busi[1*]

[1]Department of Pharmaceutics, Dr. Samuel George Institute of pharmaceutical Sciences, Markapur, Andra Pradesh, India – 523316.
[2]Department of Pharmacology, Dr. Samuel George Institute of pharmaceutical Sciences, Markapur, Andra Pradesh, India – 523316.
[3]Department of Pharmaceutical Analysis, Dr. Samuel George Institute of pharmaceutical Sciences, Markapur, Andra Pradesh, India – 523316.

Article Received on 15 Oct. 2026,
Article Revised on 05 Nov. 2026,
Article Published on 16 Nov. 2026,

https://doi.org/10.5281/zenodo.24300416

***Corresponding Author**

David Raju Busi

Department of Pharmaceutics, Dr. Samuel George Institute of pharmaceutical Sciences, Markapur, Andra Pradesh, India – 523316.

How to cite this Article: D. Steven Paul[1], V. Sudheer[1], B. Mastan[1], Prasanna Kumar Desu[1], Anusha Raouri[2], Kasietti Ashok Babu[3], Yaparthi Suneetha[3], David Raju Busi[1*] (2026). Next-Generation Pharmaceutical Innovations In Meningococcal Disease: Precision Vaccine Delivery, Nanotechnology-Enabled Therapeutics, And Advanced Formulation Engineering. World Journal of Pharmaceutical Research, 15(22), 1052–1080.
This work is licensed under Creative Commons Attribution 4.0 International license.

ABSTRACT

Meningococcal disease is a serious health issue worldwide. It is caused by Neisseria meningitidis which can cause meningitis and meningococcal infection, both which can be life threatening. Vaccination, antimicrobial therapy and supportive medical care have improved but the condition still causes significant morbidity and mortality due to its rapid progression, changing epidemiology, antibiotic resistance and limitations of modern vaccine methods. This review covers novel pharmaceutical technologies for the prevention, diagnosis and treatment of meningococcal disease, including precision vaccine delivery, nanotechnology-enabled therapeutics and advanced formulation engineering. Precision vaccine approaches such as genomic surveillance, antigen matching, reverse vaccinology and structural vaccinology can improve vaccine selection and broader protective immune responses. Using nanotechnology based on delivery systems such as liposomes, lipid nanoparticles, polymeric nanoparticles and nanoemulsions are being studied to improve drug delivery, enhance antigen stability, provide controlled drug release and

possibly improve therapeutic targeting . In addition, sophisticated formulation approaches including microencapsulation, lyophilization, spray drying, stabilizer-assisted formulations and controlled-release systems may enhance product stability, shelf life, patient acceptability and distribution. To control diseases, it is mandatory to integrate vaccination, early detection, antimicrobial treatment and modern drug delivery technologies. Safety, toxicity, clinical efficacy, regulatory clearance, manufacturing capacity, cost and accessibility remain important challenges to consider. Future research must target the development of pharmaceutical technologies which are safe, effective, stable and cost-effective, supported by relevant preclinical and clinical investigations. Overall, these emerging innovations hold great promise for improving the prevention and management of meningococcal disease and for improving public health outcomes worldwide.

KEYWORDS: Meningococcaldisease, Neisseria meningitidis, Precision vaccine delivery, Nanotechnology, Nanocarriers, Advanced formulation engineering, Controlled drug release, Vaccine development.

1. INTRODUCTION

Meningococcal disease is a major public health problem worldwide due to its rapid progression, unpredictable clinical course and potential for severe, life-threatening complications. Disease is mainly due to Neisseria meningitidis, a Gram-negative, encapsulated bacterium that usually colonizes the human nasopharynx but may occasionally invade the bloodstream and central nervous system. Invasive meningococcal disease (IMD) most often presents as meningitis and meningococcal septicemia, both of which are medical emergencies. Progress in antimicrobial therapy, supportive clinical care and preventive vaccination has not eliminated meningococcal infections as an important cause of morbidity and mortality worldwide. Long-term complications can also affect survivors, including neurological damage, hearing loss, problems with thinking and memory and physical disability. The speed of symptom development and the potential for disease to progress within hours underscores.[1-10]

Neisseria meningitidis is further divided into serogroups based on differences in the composition of the capsular polysaccharides. Of these, serogroups A, B, C, W, X and Y account for most invasive meningococcal infections worldwide. These serogroups have varying geographical and temporal distributions, which present difficulties when designing vaccination programs that are effective everyplace. Traditional meningococcal vaccines,

polysaccharide-based and protein-conjugate formulations, have dramatically improved disease prevention by eliciting protective immune responses against specific serogroups. In addition, protein-based vaccines have broadened the preventive options for serogroup B infections. However, present approaches are still limited by the differences in vaccine composition, immunogenicity, protection period and immune response in different populations.[1,10,23]

Vaccination remains the best approach to the prevention of meningococcal disease. The success of vaccination programs depends on a few factors including selection of antigens, vaccine stability, delivery systems, route of administration and the ability to induce prolonged immunological protection. Conventional vaccine preparations may require multiple doses, adjuvants and strict storage conditions to preserve potency. These requirements can generate logistical problems, especially in resource-limited settings where it is difficult to maintain an uninterrupted cold chain. In addition, differences in individual immune response, age-dependent immunological variations and the need for improved mucosal immunity are further challenges. Hence, current pharmaceutical research is growingly engaged in the area of novel delivery platforms and formulation strategies that can improve antigen stability, enhance targeted delivery, avoid administration-related hurdles, and elicit sustained immune responses.[1,5,0]

In the face of this scenario, precision vaccine delivery has become a major area of pharmaceutical innovation for avoiding the outbreak of meningococcal disease. Advanced delivery technologies are engineered to transport vaccine antigens and immunological components to appropriate biological sites and to augment their interaction with antigen presenting cells. Liposomes, polymeric nanoparticles, lipid-based carriers, microneedle systems and other targeted delivery platforms are being explored to improve antigen uptake, protect sensitive biological components and control antigen release. These approaches may also support alternative routes of administration such as intranasal, transdermal and other mucosal delivery routes. These strategies are especially relevant because the nasopharynx is the natural colonization site of N. meningitidis. Mucosal and systemic immune responses appropriate to the induction by delivery systems may be further developed to improve protection against meningococcal infection.[50,1-10]

Another promising direction in the development of next-generation pharmaceutical approaches for meningococcal disease is nanotechnology. Nanocarriers possess unique physicochemical properties like tunable particle size, surface characteristics, encapsulation capacity and controlled-release behavior. These features make them attractive candidates for vaccine delivery and therapeutic development. Lipid nanoparticles, solid lipid nanoparticles, polymeric nanocarriers, nanoemulsions and other nanoscale systems may help to protect antigens, to improve their biological stability and to control the interactions with immune cells. Nanotechnology-enabled formulations may also offer the opportunity to incorporate multiple antigens or immunostimulatory components in a single delivery platform. Nanotechnology is being investigated for the delivery of antimicrobial agents and other therapeutic molecules, and also for potential applications in vaccination. These systems may assist in overcoming formulation-related limitations and enhancing drug delivery to pertinent biological compartments. However, translating these technologies into clinical practice calls for careful assessment of their biological suitability, toxicity, biodistribution, biodegradability and long-term safety.[1-10]

Advanced formulation engineering enables the development of meningococcal pharmaceutical products that are more stable, more effective and more patient-friendly. We are studying formulation strategies, such as microencapsulation, polymer-based controlled-release systems, lyophilization, spray drying, and stabilizer-assisted formulations, to enhance the physical and chemical stability of vaccines and therapeutic agents. These technologies may reduce antigen degradation, maintain biological activity during storage, and possibly decrease reliance on traditional cold-chain infrastructure. Furthermore, controlled-release formulations may provide the possibility of decreasing frequency of administration and improving patient compliance. This means that the use of pharmaceutical excipients, biodegradable polymers, stabilizing agents and optimized manufacturing processes is necessary to obtain formulations with better shelf life, reproducibility and scalability. Such developments may be especially useful in improving vaccine access for geographically remote and resource-limited populations.[5,10]

Additionally, opportunities are presented for developing more comprehensive strategies for meningococcal disease prevention and control through the incorporation of precision delivery technologies, nanotechnology and advanced formulation engineering. The combination of these technologies can result in improved antigen presentation, controlled release of drugs,

enhanced stability of formulations and improved delivery of therapeutics. New advances in biomaterials, immunoengineering, and targeted pharmaceutical systems may also be exploited to devise future meningococcal vaccines and adjunctive therapeutic interventions. However, it is essential to point out that many of these approaches are still in the experimental or pre-clinical stages and that their potential benefits need to be demonstrated in systematic investigations and well-designed clinical studies.[1,10-23,50]

The successful implementation of these technologies will also depend on regulatory requirements, manufacturing complexity, production costs, scalability and equitable access. Thus, the development of next generation pharmaceutical innovations is an important step to address the ongoing challenges associated with meningococcal disease. Recent pharmaceutical research focuses on improving the efficacy, reliability, safety and availability of preventive and therapeutic interventions by precision vaccine delivery, nanotechnology-enabled therapeutic approaches, and advanced formulation engineering. The review focuses on the scientific principles, emerging technologies, applications, and current limitations of these novel strategies. It also considers their future potential to overcome current pharmaceutical and immunological barriers with a view to ultimately helping to prevent and better manage meningococcal disease and building more robust global public health preparedness.[1-10,23,50]

2. What is meningococcal Disease

There is a serious illness known as meningococcal disease, which is caused by the bacterium known as Neisseria meningitidis It could result in meningitis, an infection of the membranes that cover the brain and spinal cord, or meningitis, also known as sepsis, a blood-borne infection with an elevated mortality rate. The bacteria are often carried in the nose and throat and can be transmitted from one person to another through close and prolonged contact with ventilation or throat secretions. This can happen from coughing, kissing or sharing living space with somebody else. At first, the condition might appear like any other common illness, but it can progress fast and become dangerous in a short time. If you consider that you or someone you know has meningococcal disease, it is important to request a medical diagnosis and treatment as soon as possible. In addition to vaccination, public health measures and early proactive treatment of close contacts can also help reduce transmission of illness caused by some strains of meningococcal bacilli. Vaccination is one of the primary methods used to stop disease from these strains.[1-6,8,9]

3. Todays The barriers In Control & rehabilitation

Meningococcal disease is a serious medical condition caused by bacteria Neisseria meningitidis. It can lead to meningitis, an infection of the protective membranes surrounding the brain and spinal cord, or meningococcal sepsis, a life-threatening blood illness. Bacteria are often in the nose and throat and can be passed from one person to the next through close or prolonged contact with respiratory or throat secretions like coughing, intimacy, or sharing a living space. Symptoms may begin like common illnesses, but the disease can progress rapidly and be life-threatening in a short time. Therefore, immediate medical assessment and medical care are essential when meningococcal disease is suspected. Vaccination is an important tool in preventing disease caused by some meningococcal strains; public-health measures and timely antimicrobial treatment of close contacts can also help reduce transmission.[3-10,23,50]

There are challenges in preventing and treating meningococcal disease, despite the availability of vaccines and antibiotics.

Antibiotic Resistance: Recently, there has been an increase in instances caused by penicillin- and ciprofloxacin-resistant strains of Neisseria meningitidis. In some places, these resistant strains make up more than half of all reported cases. Such resistance complicates treatment protocols and emphasizes the need for vigilant surveillance and updated guidelines for clinical care.[3-10]

Evolving Epidemiology: The epidemiology of meningococcal disease is changing, with shifts in the prevalence of different serogroups and an increasing burden among adults. Previously, the disease predominantly affected infants and adolescents, but now adults, particularly those aged 30 to 60, are also at heightened risk. This trend necessitates a reevaluation of vaccination strategies to ensure broader protection across all age groups.[3-10]

Vaccination Coverage Gaps: While vaccines are effective, coverage remains incomplete. For instance, the uptake of the meningococcal B vaccine (MenB) under shared clinical decision-making frameworks remains low, with initiation rates between 20–33%. Additionally, there is no routine meningococcal vaccination for infants, working-age adults, or older adults in the USA.

Diagnostic difficulties: Early signs of meningococcal disease may look like those of less severe illnesses, potentially delaying detection and treatment. Rapid and precise diagnostic tools are essential to initiate immediate action and prevent the risk of severe outcomes.

4. Emergencies requiring vaccination strategies and more complex vaccination techniques

The response to an outbreak of meningococcal disease must be rapid, well targeted and informed by reliable information on the bacteria causing the outbreak. Public-health teams need to determine which meningococcal group is responsible, who is most at risk, and choose a vaccine that can protect against that group. Newer vaccine technologies may aid in making this response more precise and in improving vaccine design. But new technologies don't mean that a vaccine is automatically ready for immediate use. Safety, effectiveness, manufacturing capacity and regulatory approval all matter.[3-10,23,50]




Figure 1: Image Representation of Neisseria meningitidis and Nanoparticle-Based Meningococcal Vaccine Delivery System.

4.1 Precision Vaccines

Precision vaccination relies on knowledge of the circulating strain and the affected population to inform the choice of vaccine and outbreak planning. It doesn't necessarily mean building a brand new vaccine in an emergency. Instead, it helps health authorities decide whether a

vaccine on hand is likely to protect against the meningococcal group causing the outbreak.[11-14,18-22]

Genomic surveillance: Laboratory teams may evaluate the genetic characteristics of meningococcal samples to identify strain type and monitor for changes over time. That information can help public-health officials understand if cases are connected and what vaccine options might be appropriate.[18-22]

Antigen matching: Vaccines train the immune system to recognize specific bacterial components called antigens. Researchers can look at the antigens in the strain causing the outbreak and compare them to those in existing vaccines. This helps estimate how well a vaccine might match the circulating bacteria.[11-14]

Reverse vaccinology: This approach uses genetic and computer-based analysis to identify bacterial proteins that can be used as vaccine targets. Rather than growing the bacteria and testing each part, scientists can use the genomic information to narrow their search for promising antigens. This resulted in the identification of protein antigens that are used in some meningococcal B vaccines.

Structural vaccinology: Researchers are looking at the 3D shape of antigens to discover which bits are most likely to trigger a protective immune response. Such knowledge could help scientists refine or design antigens that are more easily recognized by the immune system.[11-14]

Targeted vaccination: During an outbreak, vaccination may be targeted to groups at increased risk for exposure, such as people in an affected community, school, university or other close-contact setting. The specific plan will depend on the outbreak investigation, the vaccine available and local public health guidance.[11-14]

4.2 New Antigens and Vaccine Platforms

Vaccine platforms are the technologies to deliver antigens to the immune system. Improved platforms could help researchers develop vaccines with broader coverage, stronger immune responses, or more convenient manufacturing or storage.[3-10,23,50]

Protein-subunit vaccines: These vaccines contain only certain proteins of the bacteria, not the entire bacteria. They are targeted at specific antigens so researchers can combine a

number of proteins to provide broader protection. This approach is especially important for meningococcal group B, which is immunized with protein-based vaccines, as the group's capsule is not a good target for standard capsule-based vaccine design.

Outer-membrane-vesicle vaccines: Meningococcal bacteria naturally release tiny particles from their outer membrane. These outer-membrane vesicles (OMVs) carry a number of bacterial components that can be recognised by the immune system. Some meningococcal vaccines have used OMV based approaches and these may be useful where a vaccine needs to be strain matched. Depending on how closely the vaccine components match the outbreak strain, the protection they provide may differ.

Conjugate vaccines: In these vaccines, a bacterial sugar, or polysaccharide, is linked to a carrier protein. The combo gets the immune system to mount a stronger and longer-lasting response than it could muster to the sugar alone, especially in young children. Conjugate vaccines targeting several meningococcal groups simplify protection against multiple groups, though the groups covered differ among products and programmes.[23,50]

Multivalent vaccine design: A multivalent vaccine contains antigens from more than one strain or group of meningococci. The goal is to offer wider protection with fewer distinct vaccine products. In an emergency, a multivalent vaccine is useful if it contains the group causing the outbreak and if there are sufficient doses.[3-10]

New genetic and delivery platforms: Technologies such as messenger RNA and advanced nanoparticle delivery systems are being studied across vaccine research and could provide ways to design or update vaccines more flexibly. Their role in meningococcal prevention should be carefully described: a promising research platform is not an approved vaccine ready for outbreak use. All candidates must be adequately tested for safety and efficacy, and they must be manufactured in a reliable process.[3-10,23,50]

Adjuvants and formulation research: An adjuvant is a component that helps to enhance the immune response to a vaccine. Researchers also examine how the amount and form of an antigen influence the response. These approaches may lead to more effective formulations, but the benefits must be proven through careful testing**.**

4.3 Enhancing vaccine effectiveness and access to vaccines

A vaccine can only protect a community if it is appropriate to the circulating strain, delivered in time and accepted and administered correctly. Hence, improving vaccine efficacy and availability is more than just developing a new vaccine formulation.

Rapid, evidence-based vaccine choice: Public-health teams need laboratory information, clear guidance and coordination between clinics and health authorities. If the vaccine used does not protect against the meningococcal group involved, it may not give the protection needed during an outbreak.

Vaccination and follow up are time-bound: Vaccination is not an instant shield. Some vaccine schedules require more than one dose because it takes time for the body to build an immune response. Health teams should be clear about when protection is likely and whether follow-up doses are recommended.

Reliable supply and distribution: Emergency campaigns require adequate doses, trained staff, appropriate transport and accessible vaccination sites. When an outbreak occurs, stockpiles, advance planning and coordination between regions can help reduce delays.

Cold-chain management: Many vaccines must be transported and kept in specific temperature ranges. during storage and transport. Vaccine quality is protected by temperature monitoring and reliable refrigeration, especially when doses need to be transported to remote or resource-constrained locations. Future distribution may be improved by research into more heat-stable formulations, but any product must adhere to quality and legal requirements.

·**Accessible vaccination services:** Communities can receive vaccines more easily with flexible clinic hours, mobile vaccination teams, clear information in pertinent languages, and helpful assistance for those who have scheduling or transportation issues. Without inciting needless fear, communication should outline the advantages and restrictions of vaccination.

Ongoing monitoring: Following the start of a vaccination campaign, health authorities keep an eye on new disease cases, reported adverse events, and vaccine uptake. They can use this information to determine whether the intended groups are receiving the response and whether the strategy needs to be modified.

Combining vaccination with other urgent measures: While vaccination is a valuable preventive measure, it cannot take the place of prompt medical evaluation and treatment in cases of suspected meningococcal illness As instructed by a medical professional, close contacts of a confirmed case may also require preventive antibiotics. Public health teams may use vaccinations in conjunction with case detection, treatment, and contact management during an outbreak.

5. Treatments Based on Nanotechnology

Nanotechnology-based treatments transport or administer medications using incredibly tiny materials, frequently measured in nanometers. These systems may aid in the investigation of ways to more efficiently administer antimicrobial medications, prevent medications from degrading too quickly, or target specific tissues in meningococcal disease research Although this is a promising field of study, the majority of meningococcal disease treatments based on nanotechnology are still in the experimental stage. They cannot take the place of timely diagnosis, proven antibiotics, or other emergency medical care.[5,7,8,23,24]

5.1 Targeted Drug Delivery Using Nanocarriers

Tiny delivery systems called nanocarriers are used to move medications throughout the body. Liposomes, polymer-based particles, lipid nanoparticles, and other synthetic materials are a few examples. To affect how a medication is transported and released, researchers can modify their size, surface, and composition.[29-41]

Preserving medications: A nanocarrier may prevent a medication from being metabolized too quickly in the body, extending its availability.

Managing drug release: Certain carriers are made to release their contents gradually or in reaction to specific circumstances. Researchers studying how to sustain beneficial drug levels over time may find this useful.

Improving tissue delivery: Scientists are looking into whether specific carrier designs can enhance the flow of medications to inflammatory or infected regions. Because the infection may impact the bloodstream or the membranes surrounding the brain and spinal cord, meningococcal disease presents a complex challenge.

Reducing unwanted exposure: Theoretically, exposure in other parts of the body could be decreased by directing more of a medication toward a desired site .Testing is required to show whether this results in fewer adverse effects.

5.2 Nanotechnology treatment of antimicrobials

Researchers are investigating many different ways that nanotechnology could help in the treatment of antibiotics. One approach is to use nanoparticles as carriers for existing antibiotics, improving the release or transport of the drugs. Another is to examine nanomaterials that may have their own antimicrobial activity.[26,34,39-41]

Antibiotic delivery: Nanocarriers may help the delivery of antimicrobial agents and could change their release rate. Researchers are studying whether this could increase the amount of drug at sites of infection.

Combination approaches: Carriers can be designed to hold more than one therapeutic component. Such systems could allow researchers to explore combination therapies, but each component and the overall formulation require careful evaluation.

Biofilm research: Some bacteria can form barrier groups called biofilms. Nanotechnology is being explored for the delivery of antimicrobial agents to these communities. The relevance and success of an approach is based on the infection being treated.[39-41]

Antimicrobial nanomaterials: The potential of some metal-based or surface-modified nanoparticles in order to affect microbes is explored. This potential has to be weighed against the potential that they might also harm human cells or build up in tissues.[26,34]

Improving existing treatments: In the future, nanotechnology may improve existing antibiotics rather than replace them. For meningococcal disease, however, standard clinical treatment remains essential and experimental nanotherapies should not delay urgent care.[26,34,39-41]

5.3 Safety and Efficacy and Clinical Translation

Before a nanotechnology-based therapy is used in clinical practice, researchers must demonstrate that the therapy is safe, effective, reproducibly manufactured, and appropriate for its intended use. This is a long process as the body may respond differently to nanoparticles depending on their size, shape, surface coating, ingredients and dose.[37-41,48,49]

Safety for healthy cells: Researchers need to find out if the particles or their parts could damage human cells, cause unwanted inflammation or have other bad effects.

Distribution and clearance: studies should investigate the locations in the body of the particles, their length of stay and their degradation or clearance.

Immune system responses: The body may recognize a nanoparticle as foreign. So researchers test to see if it triggers an unexpected immune response or alters the medicine's effects.

Dose and drug release: The amount of medicine carried, the timing of release and the number of doses all need careful evaluation. If a formulation releases a drug too fast or too slow, it may not provide the desired benefit.[37-41,48,49]

Consistent manufacturing: The production of nanomedicines can be technically complex. Every batch must be of consistent quality, including particle size, drug content, stability and performance.

Clinical testing: The first steps are promising lab and animal studies. Clinical trials are needed to establish safety and effectiveness in people and to compare a new approach with appropriate standard care.[48,49]

6. Pharmaceutical Formulations Advances

Pharmaceutical formulation is the process of mixing an active ingredient, such as a vaccine antigen or medicine, with other materials so that it is stable, can be produced reliably, and can be given to patients safely and conveniently. For meningococcal disease, formulation research can aid in the development of vaccines for prevention and medicines for treatment. A promising ingredient is not enough; it needs to be stable in storage, get to the patient in the right form, and be manufactured reliably.[34-38,48,49]

6.1 Improvements in stability and shelf life

A medicine or vaccine has to be of consistent quality from manufacture to administration. Some ingredients can be affected by heat, moisture, light, oxygen and repeated temperature changes. If a product no longer works If a product becomes unstable, its effectiveness may decrease, making careful formulation and storage essential.[37,42-46,48,49]

Selecting protective ingredients: Stabilisers and other formulation ingredients can help protect sensitive components such as proteins or vaccine antigens from changes during storage. The right mix depends on the product and needs to be tested to make sure it stays quality.

Freeze drying and other drying methods: Freeze-drying (lyophilization) is the removal of water from a product under controlled conditions. This can help improve the storage stability of certain medicines and vaccines. The product may require mixing with a liquid prior to use so the instructions and preparation steps must be clear and practical.

Improving packaging: Vials, syringes, seals and other packaging help to protect products from contamination, moisture, light and air. Packaging must be compatible with the formula and must be reliable during transport and storage.[42-46]

Monitoring temperature during distribution: It is important for many vaccines to be maintained within a controlled cold chain. Temperature-monitoring systems can help to identify when a product has been exposed to unsatisfactory conditions. This is especially important for products that travel long distances or are delivered to sites with limited refrigeration.[37,42-46,48,49]

Shelf life testing: Stability studies evaluate the product's change over time under various storage conditions. Such studies help to establish adequate storage conditions and shelf-life. A longer shelf life may be helpful in distribution, but must be supported by evidence that the product still meets quality standards.[37,42-46,48,49]

Investigating temperature-tolerant products: Researchers are investigating formulations that may be more tolerant to temperature changes. Such products could be useful in environments where reliable refrigeration is a challenge. However, they must still undergo rigorous testing; a formulation should never be assumed to be stable outside its approved storage conditions.[42-46]

More stability may mean less waste and easier maintenance of supplies, especially in public-health emergencies. It can also help make sure that patients are getting products that have been stored and handled properly.

6.2 Controlled Release and Patient Acceptable Formulations

A formulation affects storage, but also administration and uptake of the product by the body. Controlled-release formulations are formulations that release a medicine in a gradual or programd way. This may help to maintain drug levels over time, but whether this is appropriate will depend on the medicine and the condition being treated.[34-39,47]

For meningococcal disease, treatment decisions are urgent and should be based on established medical guidance. Controlled-release technologies are not to be presented as a substitute for a research area Controlled-release techniques are an area of research and should not be offered as a replacement for prompt, conventional antibiotic treatment. But research on dosage forms can help develop future medicines and supportive technologies.

Controlled drug release: Some delivery systems are designed to release a drug at a constant rate or under certain conditions. Researchers are investigating if this could make a drug more durable in the body.[34-39,47]

Fewer administration steps: In some areas of medicine, formulations that reduce the number of doses can make it easier to complete therapy. Any change in dosing must be shown to be safe and effective for a particular medicine.

Improved preparation and administration: Ready-to-use products or formulations that have a few planning steps can help reduce errors and save time for healthcare workers. Clear instructions are important, especially in busy clinics or emergency situations.

Exploring other delivery options: Scientists are looking at ways to deliver some medicines and vaccines, including through the nose or other ways besides injections. These methods may be more convenient in some situations, but are not automatically appropriate for meningococcal products and require careful clinical evaluation.[34-39]

Facilitating the use of products by different groups: Formulation design can take into account factors such as age, swallowing difficulties, injection volume and ease of handling. Patient-friendly design should also consider the needs of caregivers and health care workers.

6.3 Production and Scale-Up

A formulation that works in the lab still needs to be manufactured in quantities large enough to serve patients and communities. Scale-up means moving from small research batches to larger-scale production, maintaining consistent quality. This can be particularly important during outbreaks, when the demand for vaccines or medicines may increase rapidly.[37,41,48,49]

Batch-to-batch consistency: Each batch should meet established standards for identity, strength, purity, stability and performance. A product can be affected by even small changes in ingredients or manufacturing conditions, so the processes must be tightly controlled.[48,49]

Develop reliable manufacturing processes: Production methods must be effective on a small scale as well as in large facilities. Equipment adaptation, mixing conditions, temperature control, and packaging procedures may need to be modified Equipment, mixing conditions, temperature control, and packaging processes may need to be adapted as production expands.[37,41,]

Quality control and testing: Manufacturers will test raw materials, intermediate processes, and finished products. These checks are important for identifying problems early and making sure products meet the required specifications before they are sent out.

Sourcing raw materials and supplies: Vaccines as well as medicines need a continuous supply of ingredients, specialized equipment, containers, and testing materials. A shortfall anywhere in the supply chain can slow production.

Regulatory compliance: The manufacturing facilities and processes must comply with the applicable quality and safety standards. Regulatory review provides assurance that a product is manufactured consistently, and that any changes to its formulation or production are properly reviewed.

Transport and storage planning: The production process does not end when a product leaves the factory • Packing, shipping, storage and distribution all play a role in determining whether it arrives at healthcare facilities usable.

Creating flexible capacity: Preparation planning may involve maintaining the capability to produce products to meet increased demand. That means working together with manufacturers, health departments, and supply partners.

7. Integration of Vaccines, Therapeutics and Formulation Technologies

Meningococcal disease is a complex condition that cannot be solved with one vaccine or drug. This requires a plan of action linking prevention, early diagnosis, treatment and reliable product delivery. This is especially important because meningococcal disease can progress very quickly. Vaccines are to prevent disease, while antibiotics and urgent medical care are essential to treat an active infection. Advanced delivery systems and pharmaceutical formulations can support these efforts by ensuring product stability, delivery to patients reliably and ease of use.[5,11,26,34,42,50]

The technologies discussed in this section do not all have the same level of readiness. Vaccines and antibiotics are established parts of meningococcal disease prevention and care, whereas many nanotechnology-based treatments and newer delivery systems remain under investigation. Their potential should be assessed through careful research rather than assumed to be proven.[34,42,50]

7.1 Connecting Precision Vaccines to Disease Surveillance

"Understanding which meningococcal strains are circulating and which groups are most at risk is the first step in a strong prevention strategy. Laboratory surveillance, including the study of bacterial characteristics, can help public health teams to identify outbreaks and inform vaccine planning. Combined with vaccination records and local disease patterns, this information can help authorities make more targeted decisions about where and when to offer vaccines.[11-14,18-22]

Precision approaches could help this process by assisting researchers to ascertain whether vaccine antigens are relevant to the disease-causing strains. They may also assist in the design of future vaccines with carefully selected antigens. But predicting a match between a vaccine and a bacterial strain is not the same as predicting how much protection people will get. That is requires evidence from laboratory studies and clinical evaluation.

In an outbreak, accuracy is not about waiting for a brand new vaccine to be developed. This means using the best evidence available to guide the use of approved suitable vaccines, while also maintaining surveillance in case the outbreak changes. Just as important is straightforward communication: people need to understand who is getting a vaccination, why it's recommended, and when to seek medical attention.

7.2 Integration of vaccination and therapy

"Vaccination and treatment play different but complementary roles. Vaccines are a prevention tool, not a treatment for someone already seriously ill with meningococcal disease. People with symptoms that might be the disease should see a doctor urgently. Then clinicians can determine testing and treatment, including antibiotics when appropriate.

Regional guidance might also suggest preventive antibiotics for some close contacts of a confirmed case, as part of public-health teams' recommendations. This is rather than a vaccination and may be necessary because vaccines don't provide immediate protection.

These measures can help protect people and reduce further spread, but decisions about treatment and contact management should be made by health care professionals and public-health authorities.[5,11,26,34,42,50]

• Quick identification and medical assessment of individuals with possible symptoms.

• Clinical treatment for confirmed or strongly suspected disease should not be delayed.

• Vaccination when indicated for the affected population and the involved meningococcal group.

• Contact management and public health guidance to help reduce further cases.

• Monitoring will continue to monitor the outbreak and review if the response is still appropriate.

7.3 Nanotechnology and Modern Transport Systems:

Nanotechnology might benefit the meningococcal therapies of the future by providing novel approaches for drug delivery, protecting fragile components, or controlling the release of a compound. For example, researchers are examining nanocarriers that might carry antimicrobial agents and manipulate their movement or release in the body. Other work looks at whether engineered materials can maintain antimicrobial activity or help deliver medicines more effectively.[26,34,39-41]

These possibilities are encouraging, but they are still matters of research rather than proven solutions to meningococcal disease. The nanocarrier may not specifically target bacteria, reach the membranes surrounding the brain, or reduce side effects. Researchers need to determine where the particles go, how the body handles them, whether they damage healthy tissues, and whether they provide a real benefit compared if they actually attack healthy tissue and if they provide a meaningful benefit over existing treatment.

A practical development process would involve testing each system step-by-step: first for its physical and chemical properties, then in laboratory studies, and then appropriate preclinical and clinical investigations. Evidence from these stages alone can prove whether a specific technology is safe, effective and suitable for patient care.

7.4 Formulation Engineering to Improve The validity

The way a vaccine or medicine is designed influences how well it can be stored, transported, prepared and given. Practical needs are integrated into the development process of formulation engineering. Stabilizers, protective packaging, controlled manufacturing

conditions and proper storage instructions can help maintain product quality. Further research into freeze-drying or more temperature-tolerant formulations may also offer potential. Research into freeze-drying or more temperature-tolerant formulations may also offer potential advantages, especially where cold-chain access is challenging. Any such benefit must be demonstrated for the specific product.[34-38,48,49]




Figure 2: Integrated Overview of Prevention, Diagnosis, Treatment, and Pharmaceutical Formulation Development.

Patient- and health-worker-friendly design matters as well. Products that are clearly labeled, straightforward to prepare, and convenient to administer can support safer use. During an outbreak, simpler handling may help vaccination and treatment services reach people efficiently. Yet convenience cannot come at the expense of accurate dosing, product quality, or clinical safety.

Manufacturing is another essential part of formulation engineering. A product that performs well in a laboratory must still be produced consistently at a scale that can meet demand. This requires reliable supplies of raw materials, validated production methods, quality testing, and careful planning for transport and storage. and careful planning for transport and storage. A formulation that cannot be manufactured or distributed reliably will have limited public-health value, even if the underlying science is promising.

7.5 Implementation of the Technologies

The real potential is in linking these areas, rather than making individual innovations. Monitoring can help to identify the outbreak strain, vaccine research can guide the selection

or design of relevant antigens, formulation engineering can help to preserve and supply the vaccine and clinical services can provide prompt treatment for people who become unwell. Nanotechnology may offer other delivery options in the future, but it needs to be evaluated in the context of existing therapies and practical health-system needs.

This integrated model relies on access and trust as well. Vaccines and medicines have to be delivered equitably to communities and people need clear and respectful information about their benefits and limitations. Supply, storage, trained staff, transportation, and barriers that may prevent people from receiving care should be considered in public-health planning.

8. Regulatory, ethical and availability aspects

Creating new pharmaceutical technologies for meningococcal disease is more than proving an idea works in a lab. Personalized vaccines and nanotech-enabled therapeutics and advanced formulations must also meet rigorous regulatory standards, protect the rights and safety of patients and be accessible to the communities that need them. These considerations are interrelated. A treatment cannot improve public health if it is uncertain in its safety, if its benefits are inaccessible or if those most affected have not been considered in the development.[23,24,48-50]

Regulators assess each product on a case-by-case basis, looking at the ingredients, design, intended use and manufacturing process. Vaccine makers have to provide evidence that a product is produced consistently, produces an appropriate immune response and confers produces a proper immune response and gives real defense.

. Drugs being developed based on nanotechnology may require additional testing because particle size, shape, surface coating and composition can affect their behavior in the body. Regulators may have to examine the distribution of these particles, how long they remain in tissues, how they degrade and whether they cause unexpected immune or other adverse reactions. Change in formulation or in a method of production may also affect product quality and may therefore need careful review rather than being treated as a simple manufacturing adjustment.[23,24,48-50]

The process must undergo clinical trials and ongoing safety monitoring. Early lab results may show that a technology holds promise, but they alone cannot prove that it will be secure and efficient for people. Clinical studies should be designed to answer well-defined questions,

have proper comparisons and follow possible side effects. Meningococcal disease can advance rapidly and be fatal, so researchers and regulators have the difficult task of encouraging prompt progress without sacrificing safety. Emergency procedures may help speed up review where appropriate, but do not obviate the need for sound evidence, transparent decisions or ongoing monitoring after approval.

There are ethical concerns before a clinical trial is started. Participants should be given clear and comprehensible information about the purpose of the study, the possible benefits, the known risks and the unknowns, so that they can make an informed choice. This is especially important when the research involves children, people with limited access to health care, or a community that is affected by an outbreak. Researchers should be careful not to pressure people to participate and should make sure that people can ask questions and withdraw from a study according to the study's rules. The rights and welfare of individuals must still be protected when urgent public-health needs arise.[48-50]

The use of precision medicine and genome surveillance also raises new ethical questions. Samples of bacteria can be tested to identify strains and help determine vaccines. But we must be responsible when we collect and share health or genetic data. Information must be protected, used for specific public health or research purposes, and shared in ways that do not stigmatize particular communities. Trust is even more important in outbreaks. People are more likely to participate in vaccination programs or research when authorities explain how information will be used and listen respectfully to community concerns.[23,24]

Fairness is important in research as well. Participants in studies should be representative of the populations that are likely to use a product, taking appropriate measures to protect those at increased risk. If a vaccine or therapy is developed.

If a vaccine or therapy is developed using data from a particular region, researchers and organizations should consider whether the communities contributing to that knowledge can also benefit from the resulting innovation. Ethical research involves not only avoiding harm, but also sharing benefits fairly and acknowledging the contributions of participants and local health systems.

Access and affordability are major challenges for advanced pharmaceutical products. A technically effective vaccine or nanomedicine may still have limited impact if it is too

expensive, difficult to manufacture, or available only in well-resourced healthcare systems. Complex production methods, specialized equipment, and strict storage requirements can make distribution harder, particularly in remote areas or regions with limited infrastructure. Some practical barriers may be overcome in formulation engineering by increasing stability, simplifying preparation, and/or reducing dependence on strictly controlled storage. But these improvements have to be developed with real-world settings in mind and supported by evidence that the product remains safe and effective.

Formulation engineering can help overcome some practical barriers, by improving stability, simplifying preparation or reducing dependence on tightly controlled storage. But these improvements need to be designed for real-world settings and backed by evidence that the product remains safe and effective.

Access is based too on a reliable supply chain and strong local health services. Communities need specialized health workers, proper storage, clear guidance and easy access to vaccination or care. Public health authorities and manufacturers can promote more equitable access through advance planning, working with local collaborators, transparent supply arrangements and investment in regional production capacity where possible. Public communication should be culturally respectful, and in languages people understand. This will help people make informed decisions without overstating the benefits or the risks.

9.Ideas for Future Research

Future research on meningococcal disease should focus on developing prevention and treatment methods that are effective, safe and practical for diverse populations. Vaccines and antibiotics are still the backbone of prevention and care today, but novel methods such as precision vaccine design, nanotechnology-enabled delivery and advanced formulation engineering may provide new opportunities. More research on these technologies is needed before they can be regarded as established clinical solutions.[13,26-41,45,48,49]

A key direction is to improve the precision of vaccine design. Researchers may study the influence of genetic and antigenic differences between circulating Neisseria meningitidis strains on the performance of vaccines. Genomic surveillance combined with laboratory and clinical evidence can be used to identify vaccine components that provide broad, durable protection. Future studies should also examine the effectiveness of candidate vaccines in

different age groups. and populations, while recognizing that protection may vary by vaccine, strain, and individual factors.

Research should also look into whether new methods for vaccine delivery might improve immune responses or make vaccination easier. This includes study of the effect of delivery systems, adjuvants and formulation components on the magnitude and duration of immunity. Any benefit — fewer doses, broader protection, easier administration — must be demonstrated in carefully designed studies. New delivery technologies should be used to complement and not replace the established steps in assessing vaccine safety and effectiveness.[13,26-41,45,48,49]

Another priority is the clarification of the possible role of nanotechnology in antimicrobial treatment. We can study what happens with various nanocarriers in the laboratory, whether they can be trusted to transport medicines and how the body takes them up, distributes them and clears them away. Researchers must be particularly careful about safety, including potential effects on healthy cells, the immune response and organs. Because meningococcal disease can progress rapidly, future studies must also consider whether an experimental delivery system could be developed without delaying established antibiotic treatment.

The developments in pharmaceutical formulation are worthy of continued attention. Research could look into ways to protect sensitive ingredients for vaccines and medicines from heat, moisture and other conditions that can affect product quality. More stable formulations, convenient packaging and simpler preparation might help to distribute and use them in resource limited settings. These improvements must be confirmed by stability studies and by appropriate quality controls; products should only be stored and transported under approved conditions.[45,48,49]

Scalable, consistent manufacturing is another important need for research. A promising technology is of little public-health use if it cannot be produced reliably in sufficient quantities. Future work should focus on the transfer of formulations from lab development to larger-scale production while maintaining consistent quality. Researchers should also consider supply chains, availability of raw materials, Researchers should also think about the chains of supply, access to raw materials, the costs of manufacturing and possible opportunities for regional production, especially for communities who may be delayed in getting essential vaccines or medicines.[13,26-41]

Clinical research must be designed to generate evidence relevant to actual care. Studies should enrolll suitable populations, monitor safety longitudinally, and measure meaningful outcomes, like protection from disease and reliable use of products in healthcare settings. Collaboration between laboratory, clinician, manufacturer, regulator, and public-health agency can help ensure that research questions are scientifically and practically relevant. Because meningococcal disease is severe, ethical safeguards and informed consent must be maintained at the top of the research process.

In the end, we want to promote future innovation toward equity and access. Researchers should take affordability, storage needs, ease of administration and availability of trained health care workers into account from the earliest stages of product development. Working with communities can help identify barriers to vaccination and care, and make sure information is clear, respectful and culturally competent. These considerations are important to ensure that new technologies benefit well-resourced health systems as well as the populations most affected by meningococcal disease.

10. CONCLUSION

Next new pharmaceutical innovations are important for the advancement of the prevention and control of meningococcal disease. Accurate vaccine delivery enhances the targeting of antigens and induces powerful immune responses, thus improving the efficacy of vaccines. Nanotechnology-based therapeutics have offered advanced drug delivery strategies including improvement in drug stability, bioavailability, controlled release and targeted delivery. In addition, advanced formulation engineering is involved in the development of stable, safe, effective and patient friendly pharmaceutical products with enhanced therapeutic properties.[11,26,34,42,47]

Those three innovations are closely linked, as precision vaccine delivery determines how vaccine components reach the immune system, nanotechnology allows for advanced carriers for effective delivery and formulation engineering ensures stability, quality and performance of the final product. The combined use of both is very promising for the development of better meningococcal vaccines and standard treatments . More research, clinical evaluation and technology development is needed, but these advances may help to better prevent disease, improve treatment outcomes and reduce disease-related complications. In conclusion, the use of precision delivery systems, nanotechnology and advanced formulation

approaches is a promising direction in the coming years of pharmaceutical research for meningococcal disease.[11,26,34,42,47]

ACKNOWLEDGEMENT

We thankful to the management of Dr Samuel George Institute of Pharmaceutical Sciences for the providing of necessary facilities for the carry out of this review article. Our sincere thanks to the faculty who provided the assistance to complete the work.

REFERENCES

1. Stephens DS, Greenwood B, Brandtzaeg P. Epidemic meningitis, meningococcaemia, and Neisseria meningitidis. Lancet, 2007; 369(9580): 2196–2210. doi:10.1016/S0140-6736(07)61016-2.
2. Rouphael NG, Stephens DS. Neisseria meningitidis: biology, microbiology, and epidemiology. Methods Mol Biol, 2012; 799: 1–20. doi:10.1007/978-1-61779-346-2_1.
3. Rosenstein NE, Perkins BA, Stephens DS, Popovic T, Hughes JM. Meningococcal disease. N Engl J Med, 2001; 344(18): 1378–1388. doi:10.1056/NEJM200105033441807.
4. Caugant DA, Maiden MCJ. Meningococcal carriage and disease—population biology and evolution. Vaccine, 2009; 27 Suppl2: B64–B70.
5. Parikh SR, Campbell H, Bettinger JA, Harrison LH, Marshall HS, Martinon-Torres F, et al. The everchanging epidemiology of meningococcal disease worldwide and the potential for prevention through vaccination. J Infect, 2020; 81(4): 483–498. doi:10.1016/j.jinf.2020.05.079.
6. Jafri RZ, Ali A, Messonnier NE, Tevi-Bénissan C, Durrheim D, Eskola J, et al. Global epidemiology of invasive meningococcal disease. J Epidemiol Glob Health, 2013; 3(1): 3–25. doi:10.1016/j.jegh.2012.12.003.
7. Presa J, Findlow J, Vojicic J, Williams S, Serra L, et al. Epidemiologic trends, global shifts in meningococcal vaccination guidelines, and data supporting the use of MenACWY-TT vaccine: a review. Infect Dis Ther, 2019; 8: 307–333. doi:10.1007/s40121-019-0254-1.
8. Soumahoro L, Abitbol V, Vicic N, Bekkat-Berkani R, Safadi MAP, et al. Meningococcal disease outbreaks: a moving target and a case for routine preventative vaccination. Infect Dis Ther, 2021; 10: 1949–1988. doi:10.1007/s40121-021-00499-3.

9. Shen S, Findlow J, Peyrani P. Global epidemiology of meningococcal disease-causing serogroups before and after the COVID-19 pandemic: a narrative review. Infect Dis Ther, 2024; 13: 2489–2507. doi:10.1007/s40121-024-01063-5.
10. Borrow R, Findlow J. The important lessons lurking in the history of meningococcal epidemiology. Expert Rev Vaccines, 2024; 23(1): 445–462. doi:10.1080/14760584.2024.2329618.
11. Rappuoli R. Reverse vaccinology, a genome-based approach to vaccine development. Vaccine, 2001; 19(17–19): 2688–2691. doi:10.1016/S0264-410X(00)00554-5.
12. izza M, Scarlato V, Masignani V, Giuliani MM, Aricò B, Comanducci M, et al. Identification of vaccine candidates against serogroup B meningococcus by whole-genome sequencing. Science, 2000; 287(5459): 1816–1820. doi:10.1126/science.287.5459.1816.
13. Masignani V, Pizza M, Moxon ER. The development of a vaccine against meningococcus B using reverse vaccinology. Front Immunol, 2019; 10: 751. doi:10.3389/fimmu.2019.00751.
14. Seib KL, Scarselli M, Comanducci M, Toneatto D, Masignani V. Neisseria meningitidis factor H-binding protein fHbp: a key virulence factor and vaccine antigen. Expert Rev Vaccines, 2015; 14(6): 841–859. doi:10.1586/14760584.2015.1016915.
15. Holst J, Martin D, Arnold R, Campa C, Oster P, O'Hallahan J, et al. Properties and clinical performance of vaccines containing outer membrane vesicles from Neisseria meningitidis. Vaccine, 2009; 27 Suppl2: B3–B12. doi:10.1016/j.vaccine.2009.04.071.
16. Micoli F, MacLennan CA. Outer membrane vesicle vaccines. Semin Immunol, 2020; 50: 101433. doi:10.1016/j.smim.2020.101433.
17. Sanders H, Feavers IM. Adjuvant properties of meningococcal outer membrane vesicles and the use of adjuvants in Neisseria meningitidis protein vaccines. Expert Rev Vaccines, 2011; 10(3): 323–334. doi:10.1586/erv.11.10.
18. Poolman JT, Richmond P. Multivalent meningococcal serogroup B vaccines: challenges in predicting protection and measuring effectiveness. Expert Rev Vaccines, 2015; 14(9): 1277–1287. doi:10.1586/14760584.2015.1071670.
19. Toneatto D, Pizza M, Masignani V, Rappuoli R. Emerging experience with meningococcal serogroup B protein vaccines. Expert Rev Vaccines, 2017; 16(5): 433–451. doi:10.1080/14760584.2017.1308828.
20. Christodoulides M, Heckels J. Novel approaches to Neisseria meningitidis vaccine design. Pathog Dis, 2017; 75(3): ftx033. doi:10.1093/femspd/ftx033.

21. Marshall GS, et al. A comprehensive review of clinical and real-world safety data for the four-component serogroup B meningococcal vaccine (4CMenB). Expert Rev Vaccines, 2023; 22(1): 530–544. doi:10.1080/14760584.2023.2222015.
22. Findlow J, Lucidarme J, Taha MK, Burman C, Balmer P. Correlates of protection for meningococcal surface protein vaccines: lessons from the past. Expert Rev Vaccines, 2022; 21(6): 739–751. doi:10.1080/14760584.2021.1940144.
23. World Health Organization. Meningococcal vaccines: WHO position paper. WklyEpidemiol Rec, 2011; 86: 521–540.
24. World Health Organization. Meningococcal vaccines: WHO position paper on the use of multivalent meningococcal conjugate vaccines in countries of the African meningitis belt. Geneva: WHO; 2024.
25. Brito LT, Rinaldi FM, Gaspar EB, Correa VA, Gonçalves CA, Portilho AI, et al. Study of different routes of immunization using outer membrane vesicles of Neisseria meningitidis B and comparison of two adjuvants. Vaccine, 2020; 38(48): 7674–7682. doi:10.1016/j.vaccine.2020.09.081.
26. Sharma H, Narayanan KB, Ghosh S, et al. Nanotherapeutics for meningitis: enhancing drug delivery across the blood-brain barrier. Biomimetics, 2025; 10(1): 25. doi:10.3390/biomimetics10010025.
27. Garg A, Dewangan HK. Nanoparticles as adjuvants in vaccine delivery. Crit Rev Ther Drug Carrier Syst, 2020; 37(2): 183–204. doi:10.1615/CritRevTherDrugCarrierSyst.2020033273.
28. Grego EA, et al. Polymeric nanoparticle-based vaccine adjuvants and delivery vehicles. Curr Top Microbiol Immunol, 2021; 433: 29–76. doi:10.1007/82_2020_226.
29. Chatzikleanthous D, O'Hagan DT, Adamo R. Lipid-based nanoparticles for delivery of vaccine adjuvants and antigens: toward multicomponent vaccines. Mol Pharm, 2021; 18(8): 2867–2888. doi:10.1021/acs.molpharmaceut.1c00447.
30. Hou X, Zaks T, Langer R, Dong Y. Lipid nanoparticles for mRNA delivery. Nat Rev Mater, 2021; 6: 1078–1094. doi:10.1038/s41578-021-00358-0.
31. Aldosari BN, Alfagih IM, Almurshedi AS. Lipid nanoparticles as delivery systems for RNA-based vaccines. Pharmaceutics, 2021; 13(2): 206. doi:10.3390/pharmaceutics13020206.
32. Blakney AK, et al. Polymeric and lipid nanoparticles for delivery of self-amplifying RNA vaccines. J Control Release, 2021; 338: 201–210. doi:10.1016/j.jconrel.2021.08.029.

33. Khan MS, Baskoy SA, Yang C, Hong J, Chae J, Ha H, et al. Lipid-based colloidal nanoparticles for applications in targeted vaccine delivery. Nanoscale Adv, 2023; 5: 1853–1869. doi:10.1039/D2NA00795A.
34. Guimarães D, Cavaco-Paulo A, Nogueira E. Design of liposomes as drug delivery system for therapeutic applications. Int J Pharm, 2021; 601: 120571. doi:10.1016/j.ijpharm.2021.120571.
35. Pande S. Liposomes for drug delivery: review of vesicular composition, factors affecting drug release and drug loading in liposomes. Artif Cells NanomedBiotechnol, 2023; 51(1): 428–440. doi:10.1080/21691401.2023.2247036.
36. Peng T, Xu W, Li Q, Ding Y, Huang Y. Pharmaceutical liposomal delivery—specific considerations of innovation and challenges. Biomater Sci, 2023; 11: 62–75. doi:10.1039/D2BM01252A.
37. Jyothi VGSS, Bulusu R, Rao BVK, Pranothi M, Banda S, Bolla PK, et al. Stability characterization for pharmaceutical liposome product development with focus on regulatory considerations: an update. Int J Pharm, 2022; 624: 122022. doi:10.1016/j.ijpharm.2022.122022.
38. Choudhary M, Chaurawal N, Barkat MA, Raza K. Proliposome-based nanostrategies: challenges and development as drug delivery systems. AAPS PharmSciTech, 2022; 23(8): 293. doi:10.1208/s12249-022-02443-1.
39. Torchilin VP. Recent advances with liposomes as pharmaceutical carriers. Nat Rev Drug Discov, 2005; 4: 145–160. doi:10.1038/nrd1632.
40. Peer D, Karp JM, Hong S, Farokhzad OC, Margalit R, Langer R. Nanocarriers as an emerging platform for cancer therapy. Nat Nanotechnol, 2007; 2: 751–760. doi:10.1038/nnano.2007.387.
41. Mitchell MJ, Billingsley MM, Haley RM, Wechsler ME, Peppas NA, Langer R. Engineering precision nanoparticles for drug delivery. Nat Rev Drug Discov, 2021; 20: 101–124. doi:10.1038/s41573-020-0090-8.
42. Wang W. Lyophilization and development of solid protein pharmaceuticals. Int J Pharm, 2000; 203(1–2): 1–60. doi:10.1016/S0378-5173(00)00423-3.
43. Carpenter JF, Pikal MJ, Chang BS, Randolph TW. Rational design of stable lyophilized protein formulations: some practical advice. Pharm Res. 1997; 14: 969–975.
44. Maa YF, Hsu CC. Protein denaturation by combined effect of shear and air-liquid interface. BiotechnolBioeng. 1999; 54(6): 503–512.

45. 4Schoenmaker L, Witzigmann D, Kulkarni JA, Verbeke R, Kersten G, Jiskoot W, et al. mRNA-lipid nanoparticle COVID-19 vaccines: structure and stability. Int J Pharm, 2021; 601: 120586. doi:10.1016/j.ijpharm.2021.120586.
46. Liposome-polymer complex for drug delivery system and vaccine stabilization. Heliyon, 2022; 8(2): e08934. doi:10.1016/j.heliyon.2022.e08934.
47. Langer R. New methods of drug delivery. Science. 1990; 249(4976): 1527–1533. doi:10.1126/science.2218494.
48. International Council for Harmonisation. ICH Q5C: Quality of biotechnological products: stability testing of biotechnological/biological products. Geneva: ICH; 1995.
49. International Council for Harmonisation. ICH Q1A(R2): Stability testing of new drug substances and products. Geneva: ICH; 2003.
50. World Health Organization. WHO guidelines on meningitis diagnosis, treatment and care. Geneva: WHO; 2025. ISBN: 978-92-4-010804-2.